PROPYL GALLATE

Molecular Excipient

Mwt. LogP HBD HBA PSA RB CSP3
212.0 1.4 3 5 87.0 3 0.3
UNII
8D4SNN7V92
CAS
121-79-9
SYNONYMS
  • Propyl Gallate
  • Nsc-2626
  • Fema No. 2947
  • Propyl Gallate [ep]
  • Propyl Gallate [mart.]
  • Propyl Gallate [mi]
  • Propyl Gallate [inci]
  • Propyl Gallate [fcc]
  • Propyl Gallate [fhfi]
  • Propyl Gallate [ii]
  • Propyl Gallate [hsdb]
  • Propyl Gallate [usp-Rs]
  • Propyl Gallate [who-Dd]
  • Propyl Gallate [vandf]
  • Propyl Gallate (e 310)
  • Anhydrous Propyl Gallate (e 310)
  • E-310
  • Ins-310
  • Ins No.310
ZINC ID(s)
Availability
Present in 57 ZINC catalogs

Known Active Genes

There has not been any activity reported at 10μM or less for this excipient (per ChEBML)

Clinical Trials

This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
Code Date Title Phase Status
NCT02205320 2014-02-01 A Comparative, Crossover, Pharmacokinetic, Pharmacodynamic and Safety Study of Three Forms of PEG-G-CSF in Normal Healthy Volunteers Phase 1 Recruiting
NCT01980940 2013-12-01 The Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Participants With Osteoarthritis (MK-0663-168) Phase 1/Phase 2 Completed
NCT01450098 2011-10-01 A Study of LY2484595 in Healthy Subjects Phase 1 Completed
NCT00369928 2006-08-01 Evaluation of 2 Oral Doses of PG-760564 in Rheumatoid Arthritis (RA) Patients Receiving Methotrexate Phase 2 Completed
NCT00801814 2006-04-01 Effect of Escalating Doses of a Novel Viscous Polysaccharide on Postprandial Glycemia Phase 2/Phase 3 Completed
NCT00791817 2005-08-01 Study to Evaluate Potential Food Effects Phase 1 Completed
NCT00791388 2005-08-01 Multiple Rising Oral Dose Study of PG 760564 Administered Twice Daily to Healthy Male/Female Volunteers for 14 Days Phase 1 Completed
NCT00705653 2005-03-01 Study of CGC-11047 (PG-11047) in Subjects With Advanced Refractory Solid Tumors Phase 1 Completed
NCT00067236 2003-09-01 Study of Oral PG-116800 Following a Heart Attack Phase 2 Completed
NCT00041756 2002-07-01 Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee Osteoarthritis Phase 2 Completed

(Browse) Purchasable Analogs in ZINC

Functions of Propyl Gallate

Aox - Antioxidant

Dosages

Route Formulation Per Unit Dose
Intramuscular Injection
Topical Emulsion, Cream
Topical Gel 0.05%
Topical Ointment
Oral Capsule 0.16MG
Oral Capsule, Soft Gelatin 2MG
Oral Concentrate 0.02%
Oral Suspension
Oral Tablet 1.36MG
Oral Tablet, Extended Release 0.07MG
Oral Tablet, Film Coated 0.04MG
Oral Tablet, Sustained Action 0.06MG
Oral Tablet, Sustained Action, Coated 0.04MG

More Information

Usage Over Time

Comments